CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
In July, all 5 CTS laboratories will convert from the current Grifols Ultrio Plus NAT triplex assay ...
The new Learning Center website launch today on Monday, March 30, 2020. While the link to the new Le...
Creative Testing Solutions, the largest nonprofit blood testing organization in the U.S., today anno...
On April 15, 2019, the New CTS Laboratory Information System has been successfully implemented in Po...
Seasonal monitoring of epidemic triggers for West Nile Virus (WNV) NAT tested donations will begin J...
As winter weather continues to move through parts of the US, we would like to remind you it may be n...